Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

View original at finance.yahoo.com
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Merck (MRK). Shares have added about 1.7% in that time frame, outperforming the S&P 500…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Adjusted earnings per share are expected to be between $5.00 and $5.15 in 2026

    80% confidence

  • The adjusted gross margin is expected to be around 82% in 2026

    80% confidence

  • Roche Holding has a Zacks Rank #3 (Hold)

    80% confidence

  • The estimate of $70 billion was $20 billion more than its previous estimate a year ago

    80% confidence

  • The estimate of $70 billion was more than double the peak consensus estimate for Keytruda revenues of $35 billion in 2028

    80% confidence

  • Merck has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months

    80% confidence

  • A lower-than-expected infant immunization rate and high inventory levels in the market hurt Enflonsia sales in Q4 2025

    80% confidence

  • Merck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%

    80% confidence

  • In 2026, Merck expects to buy back shares worth $3 billion

    80% confidence

  • Generic competition for Januvia/Janumet, Bridion and Dificid is expected to hurt revenues by approximately $2.5 billion in 2026

    80% confidence

  • Merck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence

  • Keytruda growth was negatively impacted by approximately $200 million due to the unfavorable timing of wholesaler purchases in the United States in Q4 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? — Source | Via News | ViaNews Market